ReviewJournal of medicine and life2022
Diet, fibers, and probiotics for irritable bowel syndrome.
Review in Journal of medicine and life, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Sports Dietitians Australia and Ultra Sports Science Foundation Joint Position Statement: A Practitioner Guide to the Prevention and Management of Exercise-Associated Gastrointestinal Perturbations and Symptoms.Sports medicine (Auckland, N.Z.) · 2025Guideline
- Acupuncture vs. antispasmodics in the treatment of irritable bowel syndrome: An adjusted indirect treatment comparison meta-analysis.Frontiers in physiology · 2022Pooled it
- Effect of Lacticaseibacillus rhamnosus IDCC 3201 on irritable bowel syndrome with constipation: a randomized, double-blind, and placebo-controlled trial.Scientific reports · 2024Trial
- Efficacy of diet restriction with or without probiotic for treatment of patients with IBS-D: Phase I-II clinical trial.Immunity, inflammation and disease · 2023Trial
- Review
- Pathophysiology-driven use of natural products in irritable bowel syndrome: a review.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- From Husks and Seeds to Health: an Inevitable Outcome Rather than a Fluke.Current nutrition reports · 2026Review
- Effect of combined continuity care guided by Orem's self-care model and low FODMAP diet on gut microbiota composition and symptoms in patients with irritable bowel syndrome.BMC gastroenterology · 2026Article
- The Role of Gut Microbiota in Fish Viral Infection: Mechanisms and Microbiota-Targeted Interventions.Aquaculture nutrition · 2026Review
- Gut microbial dysbiosis associated to diarrheic irritable bowel syndrome can be efficiently simulated in the Mucosal ARtificial COLon (M-ARCOL).Bioengineered · 2025Article
- Impact of low-FODMAP diet on symptom relief in irritable bowel syndrome patients.Asia Pacific journal of clinical nutrition · 2025Article
- Microbiota in Health and Disease.Life (Basel, Switzerland) · 2025Article
- The Ten Dietary Commandments for Patients with Irritable Bowel Syndrome: A Narrative Review with Pragmatic Indications.Nutrients · 2025Review
- Article
- The effect of low-FODMAP diet on patients with irritable bowel syndrome.Scientific reports · 2025Article
- An 8-Week Course of Bifidobacterium longum 35624Probiotics and antimicrobial proteins · 2025Observational
- Life's Simple 7 and its impact on chronic bowel disorders: a study on constipation and diarrhea in the U.S. adult population.Frontiers in medicine · 2025Article
- A comprehensive overview of the effects of probiotics, prebiotics and synbiotics on the gut-brain axis.Frontiers in microbiology · 2025Review
- Wuling powder ameliorates diarrhea-predominant irritable bowel syndrome in mice by modulating gut mucosal microbiota and alleviating intestinal inflammation.Frontiers in cellular and infection microbiology · 2025Article
- Causative Factors, Clinical Manifestations, and Therapeutic Strategies for Irritable Bowel Syndrome.Cureus · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many aspects make irritable bowel syndrome (IBS) challenging for both patients and physicians. The unclear pathogenesis with many pathways to be explored, bothering symptoms that affect the quality of life, and many subtypes of the condition are only a few reasons that make IBS difficult to control and obtain satisfactory results. Treatment options start with general advice for lifestyle, continue with non-pharmaceutical treatments, and finally touch classic treatments. In this review, pharmaceutical treatment options are not accounted for. Consensus groups and meta-analyses have concluded guidelines that overall are the same, with variations in the strength of recommendations and some cultural and geographical particularities. Dietary interventions, probiotics, and fibers can be seen as non-pharmaceutical treatments that coexist in various protocols because of the relevant evidence regarding their efficacy in treating IBS symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.